Vorolanib is a small molecule commercialized by EyePoint Pharmaceuticals, with a leading Phase II program in Non-Proliferative Diabetic Retinopathy (NPDR). According to Globaldata, it is involved in 5 clinical trials, of which 2 were completed, 2 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Vorolanib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Vorolanib is expected to reach an annual total of $392 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Vorolanib Overview

Vorolanib is under development for the treatment of wet age-related macular degeneration, nonproliferative diabetic retinopathy (NPDR) diabetic macular edema. The drug candidate is a combination of a bioerodible formulation of its proprietary Durasert sustained-release technology with vorolanib. It is administered through intravitreal route. The drug candidate acts by targeting VEGF. The therapeutic candidate is developed based on Durasert technology and delivered using Medidur to provide sustained release. Medidur is a miniaturized, injectable, sustained-release drug delivery system. It was also under development for the treatment of dry age-related macular degeneration and retinal vein occlusion.

EyePoint Pharmaceuticals Overview

EyePoint Pharmaceuticals (EyePoint), formerly pSivida, is a pharmaceutical company that develops and commercializes therapies for treatment of eye disorders. The company utilizes its Duraset platform, a miniaturized, injectable, and sustained delivery system to develop its product. Its pipeline products includes EYP-1901, an investigational sustained delivery intravital anti-VEGF treatment that targets wet age-related macular degeneration (Wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macularedema (DME). The company also markets its product such as Yutiq, a fluocinolone acetonide intravitreal implant to treat chronic non-infectious uvetis; and Dexycu for treatment of postoperative inflammation. EyePoint is headquartered in Watertown, Massachusetts, the US.
The company reported revenues of (US Dollars) US$41.4 million for the fiscal year ended December 2022 (FY2022), an increase of 12.1% over FY2021. The operating loss of the company was US$101.2 million in FY2022, compared to an operating loss of US$53.2 million in FY2021. The net loss of the company was US$102.3 million in FY2022, compared to a net loss of US$58.4 million in FY2021. The company reported revenues of US$15.2 million for the third quarter ended September 2023, an increase of 67% over the previous quarter.

For a complete picture of Vorolanib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 20 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.